Citation Impact
Citing Papers
Infrared molecular fingerprinting of blood-based liquid biopsies for the detection of cancer
2021 StandoutNobel
Cancer statistics, 2023
2023 Standout
Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
2009 Standout
Cancer statistics, 2024
2024 Standout
Tumor-Educated CD11bhighIalow Regulatory Dendritic Cells Suppress T Cell Response through Arginase I
2009
Dendritic cells in cancer immunology and immunotherapy
2019 Standout
2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients
2016 Standout
Myeloid-derived suppressor cells coming of age
2018 Standout
Establishing the Diagnosis of Lung Cancer
2013 Standout
A view on drug resistance in cancer
2019 StandoutNature
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
2016 Standout
Mechanisms of tumor escape from immune system: Role of mesenchymal stromal cells
2014
Multigene Mutation Analysis of Metastatic Lymph Nodes in Non-small Cell Lung Cancer Diagnosed by Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration
2011
Hydroxycholesterol substitution in ionizable lipid nanoparticles for mRNA delivery to T cells
2022 StandoutNobel
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
2019 Standout
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
2019 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016 Standout
Integrating liquid biopsies into the management of cancer
2017
Classification and mutation prediction from non–small cell lung cancer histopathology images using deep learning
2018 Standout
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
2014 Standout
Tumor-derived factors modulating dendritic cell function
2016
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
2016 Standout
The biology and function of fibroblasts in cancer
2016 Standout
Precision Diagnosis and Treatment for Advanced Non–Small-Cell Lung Cancer
2017
Coordinated regulation of myeloid cells by tumours
2012 Standout
Cancer immunotherapy via dendritic cells
2012 Standout
Immunogenic cell death in cancer and infectious disease
2016 Standout
Current and future perspectives of liquid biopsies in genomics-driven oncology
2018 Standout
Myeloid-derived suppressor cells as regulators of the immune system
2009 Standout
Sarcoidosis
2013 Standout
Lung cancer: current therapies and new targeted treatments
2016 Standout
Immunoreceptor TIGIT inhibits the cytotoxicity of human cytokine-induced killer cells by interacting with CD155
2016
Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma
2011
British Thoracic Society guideline for advanced diagnostic and therapeutic flexible bronchoscopy in adults
2011
Dendritic Cells in the Cancer Microenvironment
2013
Regulatory T cells, tumour immunity and immunotherapy
2006 Standout
Inflammatory cell infiltration of tumors: Jekyll or Hyde
2007
Mechanisms and functional significance of tumour-induced dendritic-cell defects
2004
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial
2013
Photodynamic therapy and anti-tumour immunity
2006 Standout
Liquid biopsies come of age: towards implementation of circulating tumour DNA
2017 Standout
A Review of Cancer Immunotherapy Toxicity II: Adoptive Cellular Therapies, Kinase Inhibitors, Monoclonal Antibodies, and Oncolytic Viruses
2021
Taking dendritic cells into medicine
2007 StandoutNatureNobel
Trial watch: Dendritic cell-based anticancer therapy
2014
Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status
2014
STATs in cancer inflammation and immunity: a leading role for STAT3
2009 Standout
The tumor microenvironment and its role in promoting tumor growth
2008 Standout
Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non-small-cell lung cancer (NSCLC) patients with good performance status not progressing after first-line induction chemotherapy: Results by performance status, EGFR mutation, histology and response to previous induction
2015
VEGF-targeted therapy: mechanisms of anti-tumour activity
2008 Standout
The immune contexture in human tumours: impact on clinical outcome
2012 Standout
Microenvironmental regulation of metastasis
2008 Standout
Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer
2017 StandoutNobel
Pretreatment neutrophil-to-lymphocyte ratio is associated with outcome of advanced-stage cancer patients treated with immunotherapy: a meta-analysis
2018
Neutrophils in cancer: neutral no more
2016 Standout
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
Gefitinib for non-small-cell lung cancer treatment
2011
Single agent maintenance therapy for advanced stage non-small cell lung cancer: A meta-analysis
2012
NF-κB, inflammation, immunity and cancer: coming of age
2018 Standout
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
2016 Standout
Escape from immunotherapy: possible mechanisms that influence tumor regression/progression
2004
Endobronchial Ultrasound–guided Transbronchial Needle Aspiration Prevents Mediastinoscopies in the Diagnosis of Isolated Mediastinal Lymphadenopathy
2012
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
2018 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Vascular Endothelial Growth Factor-Trap Overcomes Defects in Dendritic Cell Differentiation but Does Not Improve Antigen-Specific Immune Responses
2007
Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected
2015
Tumor-Infiltrating Dendritic Cells in Cancer Pathogenesis
2015
Dendritic Cells and Tumor Microenvironment: A Dangerous Liaison
2006
Prospective Validation of Rapid Plasma Genotyping for the Detection ofEGFRandKRASMutations in Advanced Lung Cancer
2016
Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update
2017 Standout
Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer
2016
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
2016 Standout
Perioperative Systemic Therapy for Resectable Non–Small Cell Lung Cancer
2022
Regulation of Dendritic Cell Differentiation and Antitumor Immune Response in Cancer by Pharmacologic-Selective Inhibition of the Janus-Activated Kinase 2/Signal Transducers and Activators of Transcription 3 Pathway
2005
Progress and prospects of early detection in lung cancer
2017
The Tumor Microenvironment Innately Modulates Cancer Progression
2019 Standout
Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
2015
Sustained expansion of NKT cells and antigen-specific T cells after injection of α-galactosyl-ceramide loaded mature dendritic cells in cancer patients
2005 StandoutNobel
Molecular Origin of Blood‐Based Infrared Spectroscopic Fingerprints**
2021 StandoutNobel
Targeted therapy for non-small cell lung cancer: current standards and the promise of the future.
2015
Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Non–Small-Cell Lung Cancer: AVAPERL (MO22089)
2013
Works of Baohui Han being referenced
ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study
2016
<p>Tyrosine Kinase Inhibitor-Related Hepatotoxicity in Patients with Advanced Lung Adenocarcinoma: A Real-World Retrospective Study</p>
2020
Quantification of Rare Circulating Tumor Cells in Non-Small Cell Lung Cancer by Ligand-Targeted PCR
2013
Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial
2012
Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer
2011
A prospective study of the efficacy of a combination of autologous dendritic cells, cytokine-induced killer cells, and chemotherapy in advanced non-small cell lung cancer patients
2013
Endobronchial ultrasound-guided transbronchial needle aspiration for staging of lung cancer: A systematic review and meta-analysis
2009
Intratumoral cytokines/chemokines/growth factors and tumor infiltrating dendritic cells: friends or enemies?
2006
Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase III trial
2013
Final Overall Survival Results from a Phase III, Randomized, Placebo-Controlled, Parallel-Group Study of Gefitinib Versus Placebo as Maintenance Therapy in Patients with Locally Advanced or Metastatic Non–Small-Cell Lung Cancer (INFORM; C-TONG 0804)
2015
Determining the Prevalence of EGFR Mutations in Asian and Russian Patients (PTS) with Advanced Non-Small-Cell Lung Cancer (ANSCLC) of Adenocarcinoma (ADC) and Non-Adc Histology: Ignite Study
2015
Investigating the Utility of Circulating-Free Tumour-Derived Dna (CTDNA) in Plasma for the Detection of Epidermal Growth Factor Receptor (EGFR) Mutation Status in European and Japanese Patients (PTS) with Advanced Non-Small-Cell Lung Cancer (ANSCLC): Assess Study
2015
Origin and pharmacological modulation of tumor‐associated regulatory dendritic cells
2014
BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non–Small-Cell Lung Cancer
2015
Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients
2019
Optimizing dendritic cell-based immunotherapy for cancer
2007
580_PR: Clinical and demographic features that influence EGFR mutation detection in plasma from patients (pts) with aNSCLC: The ASSESS experience
2016
[Vascular endothelial growth factor inhibits dendritic cells from patients with non-small cell lung carcinoma].
2003
Efficacy, tolerability, and biomarker analyses from a phase III, randomized, placebo-controlled, parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) (INFORM; C-TONG 0804).
2011